Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With

Indication
Prostatic Neoplasms

Other upcoming events for CTTH

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivatio
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abir

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With — CTTH Phase 3 Readout | BioSniper